FDA Approves Apple AirPods Pro as First Over-the-Counter Hearing Aid Software

The FDA granted marketing authorization for Apple's Hearing Aid Feature as the first over-the-counter hearing aid software device under the De Novo regulatory pathway, targeting individuals aged 18 and older with mild to moderate hearing loss. Clinical validation trials involving 118 participants demonstrated that self-fitting using the AirPods Pro achieved hearing improvement outcomes statistically equivalent to professional audiologist fittings, with no adverse events recorded. The technology represents a significant regulatory milestone integrating medical-grade amplification into consumer audio hardware.

The FDA's authorization marks the first instance of software-based hearing assistance receiving clearance as an over-the-counter medical device rather than requiring professional fitting. Apple's system uses the AirPods Pro hardware paired with self-administered audiometric testing and adaptive signal processing performed on the device itself. The clinical evidence supporting approval came from a 118-person trial comparing independent user setup against traditional audiologist configuration, with both approaches producing equivalent outcomes in speech recognition and perceived benefit.

Regulatory bodies across major markets have adopted varying timelines and frameworks for the same technology. While U.S. approval occurred in September 2024, the United Kingdom required separate medical device registration through the MHRA, delaying UK availability to early 2025. The European Union's process similarly involved notified bodies assessing conformity with medical device regulations. This fragmented international approach reflects divergent administrative requirements despite identical underlying technology and clinical data.